Feedback Inhibition of Catecholamine Release by Two Different α 2 -Adrenoceptor Subtypes Prevents Progression of Heart Failure

Publisher Website
Google Scholar
Abstract
Background— Elevated plasma norepinephrine levels are associated with increased mortality in patients and in animal models with chronic heart failure. To test which α 2 -adrenoceptor subtypes operate as presynaptic inhibitory receptors to control norepinephrine release in heart failure, we investigated the response of gene-targeted mice lacking α 2 -adrenoceptor subtypes (α 2 -KO) to chronic left ventricular pressure overload. In addition, we determined the functional consequences of genetic variants of α 2 -adrenoceptors in human patients with chronic heart failure. Methods and Results— Cardiac pressure overload was induced by transverse aortic constriction. Three months after aortic banding, survival was dramatically reduced in α 2A -KO (52%) and α 2C -KO (47%) mice compared with wild-type and α 2B -deficient (86%) animals. Excess mortality in α 2A - and α 2C -KO strains was attributable to heart failure with enhanced left ventricular hypertrophy and fibrosis and elevated circulating catecholamines. The clinical importance of this finding is emphasized by the fact that heart failure patients with a dysfunctional variant of the α 2C -adrenoceptor had a worse clinical status and decreased cardiac function as determined by invasive catheterization and by echocardiography. Conclusions— Our results indicate an essential function of α 2A - and α 2C -adrenoceptors in the prevention of heart failure progression in mice and human patients. Identification of heart failure patients with genetic α 2 -adrenoceptor variants as well as new α 2 -receptor subtype–selective drugs may represent novel therapeutic strategies in chronic heart failure and other diseases with enhanced sympathetic activation.